Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability and pharmacokinetics of ABT-199 (venetoclax) in female patients with systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Venclexta (venetoclax)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Lupus Erythematosus | Phase 1 | Status: COMPLETED